To evaluate the incidence of preterm birth (PTB) amongst patients with amniotic fluid sludge according to whether or not they had been treated with antibiotics following initial diagnosis. Additional maternal and neonatal outcomes were evaluated according to cohort. STUDY DESIGN: We performed a retrospective cohort study of all patients diagnosed with amniotic fluid sludge in the outpatient ultrasound suite at a single academic center between 2010-2017. Patients were separated into cohorts based on whether or not they had been treated with antibiotics at the time of diagnosis. Patients with multiple gestation, fetal anomalies, pre-viable preterm rupture of membranes prior to initial diagnosis of amniotic fluid sludge, active preterm labor, placenta previa and/or suspected accreta were excluded. Primary outcome of preterm birth was compared by univariate analysis as well as regression analysis, so as to control for potential co-linear and/or confounding variables. Additional outcomes were compared by univariate analysis. RESULTS: A total of 181 patients were identified and considered for inclusion. 97 met inclusion criteria. Of those, 51 were treated with PO antibiotics (46 with PO azithromycin and 5 with PO moxifloxacin) and 46 were not treated. The incidence of PTB < 37 wks was 49.4 % (48/97) and PTB < 28 wks was 22.7% (22/97). There was no significant difference in incidence of preterm birth between the two cohorts, either < 37 weeks (p¼0.47) or < 28 weeks (p¼0.83). After adjusting for race, BMI, tobacco use, cervical length and PTB history, the incidence of PTB with antibiotic treatment remained insignificant (OR 1.3, 0.77-1.9). No differences were seen in the incidence of PPROM (p¼0.94) or mean latency from diagnosis (p¼0.95). Neonatal outcomes including birthweight (p¼0.77), sepsis (p¼0.53), IVH (p¼0.95), LOS (p¼0.46), and NICU admission (p¼0.08) were not different between cohorts. There was no difference in the incidence of either clinical or pathologic chorioamnionitis between cohorts (p¼0.92 and 0.14, respectively). CONCLUSION: Antibiotic treatment administered after the initial diagnosis of amniotic fluid sludge is not associated with a reduction in the rates of premature birth when compared to expectant management. Likewise, treatment of amniotic fluid sludge was not associated with improvement in evaluated obstetric, pathologic, or neonatal variables compared to expectant management. These findings demonstrate the need for a prospective trial.
1056 Placental corticotrophin-releasing hormone (pCRH) as a possible modulator of human fetal liver blood perfusion Charité University Medicine, Berlin, Berlin OBJECTIVE: Fetal liver blood flow (fLBF) has recently emerged as a process of interest in terms of its putative role in influencing fetal growth and subsequent newborn and infant body composition (fat mass percentage). However, the determinants of variation in fLBF are poorly understood. Placental corticotrophin-releasing hormone (pCRH) has been implicated as a key endocrine mediator of placental-fetal perfusion, birth outcomes, and subsequent infant developmental and health outcomes.The objective of the present study was to determine whether circulating levels of pCRH across gestation are associated with fLBF. STUDY DESIGN: A prospective study was conducted in a cohort of 79 uncomplicated singleton pregnancies. Fetal ultrasonography was performed at 30 weeks gestation for conventional fetal biometry and characterization of fLBF (quantified by subtracting ductus venosus flow from umbilical vein flow). pCRH was quantified in maternal circulation at approximately 12, 20 and 30 weeks gestation. Multiple regression analysis was used to determine the proportion of variation in fLBF explained by pCRH. Co-variates included maternal age, parity, pre-pregnancy body mass index, gestational weight gain, gestational age at birth, and infant sex. RESULTS: fLBF at 30 weeks was 68.4 AE 4.1 ml/min. pCRH concentrations in early, mid and later gestation were 12.5 AE 0.91 pg/ml (mean AE SEM), 35.7 AE 2.77 pg/ml, and 247.9 AE 18.88 pg/ml, respectively. pCRH assessed at 12 weeks and 20 weeks was not associated with fLBF. pCRH at 30 weeks was significantly and positively associated with fLBF (r ¼ 0.319, p ¼ 0.004). After accounting for the effects of covariates, pCRH at 30 weeks gestation explained 11.6% of the variance in fLBF. CONCLUSION: Placental CRH is a possible modulator of fLBF, and may constitute a biochemical marker for clinical investigational and OBJECTIVE: Anterior uterocervical angle (aUCA), an alternative to cervical length (CL) screening, involves measurement of the angle between the anterior lower uterine segment (LUS) and cervix. However, Anterior uterocervical angle (aUCA), an alternative to cervical length (CL) screening, involves measurement of the angle between the anterior lower uterine segment (LUS) and cervix. However, studies have not consistently shown this to be a reliable predictor of spontaneous preterm birth (sPTB). Posterior uterocervical angle (pUCA), an alternative to the aUCA, measures the angle at the posterior LUS. pUCA has been evaluated in third trimester prediction of labor induction success. To date, there are no studies of pUCA in the second trimester. Our objective is to evaluate if second trimester pUCA is predictive of sPTB <37w. STUDY DESIGN: Retrospective cohort study of singletons with CL screening from 2014-2016. Post-hoc pUCA was measured on the shortest, best CL between 16-24w. (Figure) pUCA was evaluated as a continuous variable and using thresholds of >95 and >105 (based on previous aUCA data). The primary outcome was sPTB <37w. Secondary outcomes were sPTB<32w and performance metrics. ROC curves were generated for pUCA, aUCA, and CL. RESULTS: 240 women were included: 10.8% with sPTB<37w and 2.5% with sPTB<32w. There was no difference in mean pUCA in women with or without sPTB<37w (p¼0.14; , and remained significant after adjusting for prior sPTB, tobacco use, and CL (p¼0.007). Only pUCA >105 was associated with sPTB<32w (p¼0.04). There was no difference in mean aUCA or aUCA >95 and >105 for sPTB <37 or <32w. Overall, pUCA >105 had a sensitivity of 100% and specificity of 43.5% for sPTB<32w. Based on the ROC for sPTB<32, a pUCA angle >135 had a sensitivity of 83.3% and specificity of 70.3%. Both pUCA and CL were predictive of sPTB<32w and were superior to aUCA (pUCA: ROC AUC 0.83, p<0.001; CL: ROC AUC 0.78, p¼0.002; aUCA: ROC AUC 0.53, p¼0.82). CONCLUSION: In singletons, pUCA was not associated with sPTB <37w. pUCA>105 was associated with sPTB<32w but our analysis suggests that an angle of >135 may be a better cut off. Overall, pUCA is superior to aUCA in the prediction of sPTB<32w however, use as an alternative, or in addition, to CL requires further study.
Disparities in nuchal translucency uptake in California
Toki Fillman, Jamie Matteson, Stan Sciortino, Sona Saha Genetic Disease Screening Program California Department of Public Health, Richmond, CA OBJECTIVE: Including nuchal translucency (NT) ultrasound in prenatal screening risk assessment improves gestational dating and detection rates of Down syndrome and Trisomy 18. Ensuring all women have equitable access to prenatal screening options is a goal of the California Prenatal Screening Program. Currently, not all women who undergo prenatal screening choose to have a first trimester NT ultrasound. We sought to examine whether age, income, race/ethnicity or distance to an NT provider has an effect on rates of NT uptake in California. STUDY DESIGN: We examined first trimester NT ultrasound uptake for patients who participated in the California Prenatal Screening Program from January 1 through December 31, 2016. Patient addresses were geocoded, assigned to census tracts with median household income data from the 2016 American Community Survey, and matched to nearest NT provider. Univariate and multivariable logistic regression models were fit including maternal age, race/ ethnicity, distance to nearest NT provider, and income as predictors and NT uptake as the outcome.
